Institute of Cell Biology Murray Lecture 2017: Adrian Krainer (Cold Spring Harbour Laboratory) - Antisense Therapy for Spinal Muscular Atrophy: Harnessing the Power of a Backup Gene

  • Title:  Antisense Therapy for Spinal Muscular Atrophy: Harnessing the Power of a Backup Gene
  • When:  Wednesday 22 November 2017
  • Time: 4 pm
  • Location:  Michael Swann, Main Lecture Theatre, King's Building's, Edinburgh
  • Speaker:  Adrian Krainer, St Giles Professor of Molecular Genetics and Program Chair of Cancer & Molecular Biology, Cold Spring Harbor Laboratory
  • Host: Gracjan Michlewski
  • Registration: This seminar is free to attend but ticketed, please register at EVENTBRITE
  • This event is supported by The Darwin Trust of Edinburgh

Prof. Adrian Krainer is the St Giles Professor of Molecular Genetics and Program Chair of Cancer & Molecular Biology at Cold Spring Harbor Laboratory, which he joined in 1986. He received a B.A. in Biochemistry from Columbia University and a Ph.D. in Biochemistry from Harvard University. His laboratory studies pre-mRNA splicing regulation, and is also engaged in developing targeted therapies to correct or modulate alternative splicing in genetic diseases and cancer. Together with Ionis Pharmaceuticals, they developed nusinersen (SpinrazaTM), anantisense-oligonucleotide drug that corrects defective splicing of the SMN2 gene and is the first FDA/EMA-approved therapy for spinal muscular atrophy, an inherited motor-neuron disease. Prof. Krainer is a Pew Biomedical Scholar, a MERIT-award recipient from the NIH, a past President of the RNA Society, and a member of the American Academy of Arts and Sciences and the Royal Society of Medicine. He has authored ~200 publications and 16 patents.

 

Story tags: 

Please tell us what you think about this website !

What do you think of the Edinburgh Infectious Diseases website?  We would be very grateful if you could spare 2 minutes to help us improve the useability and look of our pages. Thank you for your help !